# Study of YH004 (4-1BB Agonist Antibody) in Advanced or Metastatic Malignancy

> **NCT05040932** · PHASE1 · COMPLETED · sponsor: **Eucure (Beijing) Biopharma Co., Ltd** · enrollment: 8 (actual)

## Conditions studied

- Cancer

## Interventions

- **DRUG:** YH004

## Key facts

- **NCT ID:** NCT05040932
- **Lead sponsor:** Eucure (Beijing) Biopharma Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-12-07
- **Primary completion:** 2023-07-16
- **Final completion:** 2023-07-16
- **Target enrollment:** 8 (ACTUAL)
- **Last updated:** 2023-09-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05040932

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05040932, "Study of YH004 (4-1BB Agonist Antibody) in Advanced or Metastatic Malignancy". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT05040932. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*